Skip to main content
TiumBio Co., Ltd. logo

TiumBio Co., Ltd. — Investor Relations & Filings

Ticker · 321550 ISIN · KR7321550006 KO Professional, scientific and technical activities
Open in API
Filings indexed 296 across all filing types
Latest filing 2019-11-29 Director's Dealing
Country KR South Korea
Listing KO 321550

About TiumBio Co., Ltd.

http://www.tiumbio.com/en/

TiumBio is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapeutics for rare and incurable diseases. The company's pipeline targets conditions with high unmet medical needs, including fibrotic diseases, cancer, and rare hematological disorders. Its lead assets include Merigolix (TU2670), an oral GnRH antagonist in clinical development for endometriosis and uterine fibroids, and TU7710, a long-acting recombinant activated factor VII for hemophilia. TiumBio also develops small molecule antagonists targeting the TGF-β signaling pathway for applications in oncology and fibrosis. The company advances its programs through clinical development and strategic global partnerships.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean financial authorities. This type of filing is used to disclose insider trading or changes in share ownership by company directors and executives. According to the provided definitions, this corresponds to 'Director's Dealing' (DIRS).
2019-11-29 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard disclosure form used in South Korea (DART system) for reporting insider transactions or changes in share ownership by company directors and executives. Based on the provided definitions, this corresponds to 'Director's Dealing' (DIRS).
2019-11-29 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report of Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. This type of filing is used to disclose personal share transactions by company directors and executives, which corresponds to the 'Director's Dealing' category.
2019-11-29 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean regulatory authorities (Financial Supervisory Service/Korea Exchange). This type of filing is specifically used to disclose insider trading or changes in share ownership by company directors and executives. According to the provided definitions, this corresponds to 'Director's Dealing'.
2019-11-29 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the acquisition of shares by '한국투자 글로벌 제약산업 육성 사모투자전문회사' in the company '티움바이오'. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema, as it reports significant ownership changes crossing regulatory thresholds.
2019-11-29 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Major Shareholding Notification Classification · 100% confidence The document is a Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard disclosure form required by the Financial Supervisory Service (FSS) in South Korea when a major shareholder or executive changes their stake in a company. Based on the provided definitions, this falls under the category of 'Major Shareholding Notification' (MRQ) as it details the ownership status and changes in shareholding for a major shareholder (Korea Investment Global Pharma-Ecosystem Private Equity Fund) in the company TiumBio.
2019-11-29 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.